Actively Recruiting
Quantitative Testing of Patient and Prescriber Knowledge About GATTEX (Teduglutide) for Injection Safety and Use Information
Led by Takeda · Updated on 2026-01-26
600
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a survey to understand how well participants and physicians know how to use GATTEX, a treatment for Short Bowel Syndrome (SBS), and to identify potential risks. This survey is part of a safety program called the Risk Evaluation and Mitigation Strategy (REMS), required by the US FDA to ensure certain medicines with serious risks are used safely. The main goal is to assess knowledge about the necessary checkups and tests while using GATTEX and the possible risks involved. The survey is non-interventional and participants include those who have taken GATTEX within 60 days before the survey and healthcare providers in the US who have prescribed GATTEX at least once. The survey can be completed online, by telephone, or on paper, based on the participant's preference. No study medicines are provided during this research. Participants will answer questions to measure their understanding of GATTEX safety and use. Researchers will count how many provide correct answers and how well they understand the knowledge areas of the survey. This assessment occurs every two years as part of ongoing safety monitoring. The survey aims to help improve safe use of GATTEX over time.
CONDITIONS
Brief Title
A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants aged 18 years or older who have taken GATTEX within 60 days before the survey
- Caregivers may participate on behalf of eligible participants unable to complete the survey
- Healthcare providers (adult and pediatric) in the United States who have prescribed GATTEX at least once
- Healthcare providers must provide a valid 10-digit National Provider Identifier (NPI) number
- Participants and healthcare providers who have previously participated in a GATTEX Knowledge Assessment Survey are eligible
You will not qualify if you...
- Individuals who do not agree to participate in the survey
- Respondents currently working for or with immediate family members working for Takeda Pharmaceuticals U.S.A., Inc., NPS Pharmaceuticals, Inc., Shire, UBC, or the FDA
- Individuals who report having a conflict of interest
- Healthcare providers who have opted out of receiving communications about the current survey wave
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - Up to 2 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit (remote or in-person)
Duration - 1 day
Participants complete a survey assessing their knowledge about GATTEX (Teduglutide) for injection safety and use information.
1 survey completion session (remote or in-person)
Trial Site Locations
Total: 1 location
1
Takeda Pharmaceuticals, U.S.A., Inc.
Cambridge, Massachusetts, United States, 02142
Actively Recruiting
Research Team
T
Takeda Contact
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here